Global GLP-1 Drug Peptide API Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global GLP-1 Drug Peptide API market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.

GLP-1 (Glucagon-Like Peptide-1) drugs are a class of drugs used to treat type 2 diabetes and obesity, usually prepared in the form of polypeptides. These drugs mimic the GLP-1 hormone in the body, causing the release of insulin and controlling blood sugar levels. Peptide APIs are the starting components of these drugs, typically synthesized or produced in laboratories and used in further formulation preparations.

This report is a detailed and comprehensive analysis for global GLP-1 Drug Peptide API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global GLP-1 Drug Peptide API market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2020-2031

Global GLP-1 Drug Peptide API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2020-2031

Global GLP-1 Drug Peptide API market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2020-2031

Global GLP-1 Drug Peptide API market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/Ton), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for GLP-1 Drug Peptide API

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global GLP-1 Drug Peptide API market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CPC Scientific, Novo Nordisk, Teva Pharmaceutical Industries Ltd, JYMedtech, Zhejiang Peptites Biotech, Shengnuo Biotechnology, Suzhou Tianma Pharmaceutical, SINOPEP, WuXi AppTec, HYBIO Pharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

GLP-1 Drug Peptide API market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Semaglutide
Liraglutide
Tilpotide

Market segment by Application
Diabetes
Obesity
Other

Major players covered
CPC Scientific
Novo Nordisk
Teva Pharmaceutical Industries Ltd
JYMedtech
Zhejiang Peptites Biotech
Shengnuo Biotechnology
Suzhou Tianma Pharmaceutical
SINOPEP
WuXi AppTec
HYBIO Pharmaceutical

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe GLP-1 Drug Peptide API product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of GLP-1 Drug Peptide API, with price, sales quantity, revenue, and global market share of GLP-1 Drug Peptide API from 2020 to 2025.

Chapter 3, the GLP-1 Drug Peptide API competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the GLP-1 Drug Peptide API breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and GLP-1 Drug Peptide API market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of GLP-1 Drug Peptide API.

Chapter 14 and 15, to describe GLP-1 Drug Peptide API sales channel, distributors, customers, research findings and conclusion.